MCID: ADN016
MIFTS: 70

Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 29 55 6 44 15 73
Adenocarcinomas 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 44 D000230
NCIt 50 C2852
SNOMED-CT 68 35917007
UMLS 73 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to mucinous adenocarcinoma and gastric papillary adenocarcinoma. An important gene associated with Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Abraxane and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Adenocarcinoma (/�?ædɪno�?k�?ːrsɪ�?no�?m�?/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1343)
# Related Disease Score Top Affiliating Genes
1 mucinous adenocarcinoma 34.0 CDKN2A EGFR KRAS MLH1
2 gastric papillary adenocarcinoma 33.9 ERBB2 TP53
3 cervical adenocarcinoma 33.8 CDKN2A ERBB2 TP53
4 aggressive digital papillary adenocarcinoma 33.8 HRAS KRAS PIK3CA
5 pancreas adenocarcinoma 33.8 AKT1 CDKN2A CTNNB1 EGFR EPCAM ERBB2
6 fallopian tube endometrioid adenocarcinoma 33.7 CDKN2A ERBB2
7 mucinous lung adenocarcinoma 33.7 EGFR ERBB2 HRAS KRAS
8 ovary adenocarcinoma 33.7 ERBB2 HRAS KRAS PIK3CA TP53
9 endometrial adenocarcinoma 33.6 AKT1 CDKN2A CTNNB1 EGFR ERBB2 KRAS
10 urachal adenocarcinoma 33.6 BRAF KRAS
11 barrett's adenocarcinoma 33.6 CDKN2A ERBB2 KRAS TP53
12 vulvar adenocarcinoma 33.6 RB1 TP53
13 colorectal adenocarcinoma 33.5 BRAF CTNNB1 EGFR HRAS KRAS MLH1
14 nasal cavity adenocarcinoma 33.5 CDKN2A HRAS KRAS TP53
15 uterine corpus serous adenocarcinoma 33.5 ERBB2 PIK3CA TP53
16 cecum adenocarcinoma 33.4 HRAS KRAS MLH1
17 esophagus adenocarcinoma 33.3 ERBB2 HNF1A-AS1 SMAD4 TP53
18 bile duct adenocarcinoma 33.3 AKT1 EPCAM HRAS KRAS TP53
19 barrett esophagus 33.2 CDKN2A CTHRC1 ERBB2 TP53
20 rare adenocarcinoma of the breast 33.2 AKT1 KRAS PIK3CA TP53
21 breast adenocarcinoma 33.2 AKT1 EGFR ERBB2 H19 KRAS PIK3CA
22 adenosquamous carcinoma 33.0 EGFR KRAS PIK3CA TP53
23 suppression of tumorigenicity 12 32.9 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
24 gastric adenocarcinoma 32.8 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
25 lung cancer susceptibility 3 32.6 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
26 adenoma 32.4 BRAF CTNNB1 KRAS MLH1 SMAD4 TGFBR2
27 renal cell carcinoma, papillary, 1 32.4 BRAF ERBB2 FGFR3 HRAS PIK3CA TP53
28 esophageal cancer 32.3 AKT1 CDKN2A CTNNB1 EGFR ERBB2 H19
29 colorectal adenoma 32.3 CTNNB1 HRAS KRAS MLH1 TP53
30 cystadenocarcinoma 32.3 AKT1 ERBB2 HRAS PIK3CA TP53
31 carcinosarcoma 32.3 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
32 adenoid cystic carcinoma 32.2 AKT1 CTNNB1 ERBB2 HRAS KRAS PIK3CA
33 primary peritoneal carcinoma 32.1 EGFR ERBB2 TP53
34 lung cancer 32.0 AKT1 BRAF CDKN2A EGFR EPCAM ERBB2
35 adenosquamous lung carcinoma 31.9 EGFR ERBB2 FGFR3 HRAS KRAS PIK3CA
36 pancreatic cancer 31.7 AKT1 CDKN2A CTNNB1 EGFR ERBB2 H19
37 ovarian serous cystadenocarcinoma 31.7 AKT1 BRAF ERBB2 HRAS PIK3CA TP53
38 prostate cancer 31.6 AKT1 CTNNB1 EGFR ERBB2 H19 HRAS
39 serous cystadenocarcinoma 31.6 AKT1 ERBB2 HRAS PIK3CA TP53
40 rectal neoplasm 31.6 HRAS KRAS MLH1 TP53
41 ovarian cancer 31.6 AKT1 BRAF CTNNB1 EGFR EPCAM ERBB2
42 hidradenocarcinoma 31.6 EGFR ERBB2 TP53
43 endometrial cancer 31.4 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
44 gastric cancer 31.3 AKT1 CDKN2A CTNNB1 EGFR ERBB2 H19
45 bladder cancer 31.3 CDKN2A EGFR ERBB2 FGFR3 H19 HNF1A-AS1
46 small cell carcinoma 31.1 CDKN2A EGFR TP53
47 colorectal cancer 31.0 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
48 peutz-jeghers syndrome 31.0 CTNNB1 SMAD4 TP53
49 colitis 30.9 AKT1 CTNNB1 MLH1 SMAD4
50 small cell cancer of the lung 30.8 AKT1 CDKN2A EGFR PIK3CA RB1 TP53

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 69)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.24 HRAS KRAS PIK3CA BRAF EGFR
2 Decreased viability GR00106-A-0 11.24 KRAS
3 Decreased viability GR00107-A-1 11.24 TGFBR2
4 Decreased viability GR00221-A-1 11.24 AKT1 FGFR3 HRAS KRAS PIK3CA CDKN2A
5 Decreased viability GR00221-A-2 11.24 AKT1 FGFR3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-3 11.24 AKT1 FGFR3 HRAS CDKN2A ERBB2 TGFBR2
7 Decreased viability GR00221-A-4 11.24 AKT1 PIK3CA CDKN2A ERBB2 TGFBR2 BRAF
8 Decreased viability GR00301-A 11.24 KRAS BRAF
9 Decreased viability GR00381-A-1 11.24 KRAS BRAF
10 Decreased viability GR00402-S-2 11.24 AKT1 FGFR3 HRAS KRAS PIK3CA CDKN2A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.43 FGFR3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.43 TGFBR2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.43 PIK3CA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.43 TGFBR2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.43 ERBB2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.43 TGFBR2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.43 TGFBR2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.43 TGFBR2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.43 AKT1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.43 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.43 TGFBR2
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.43 PIK3CA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.43 FGFR3
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.43 AKT1 ERBB2 FGFR3 PIK3CA TGFBR2
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.43 TGFBR2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.43 TGFBR2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.43 ERBB2
28 Decreased viability in esophageal squamous lineage GR00235-A 10.13 BRAF CDKN2A CTNNB1 ERBB2 FGFR3 HRAS
29 Decreased cell migration GR00055-A-1 10.11 AKT1 BRAF CTNNB1 EGFR ERBB4 FGFR3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.04 RB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.04 CTNNB1 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.04 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.04 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.04 KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.04 RB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.04 RB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.04 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.04 PIK3CA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.04 AKT1 PIK3CA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.04 BRAF PIK3CA
41 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.04 KRAS
42 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.04 RB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.04 AKT1 BRAF CTNNB1 KRAS PIK3CA RB1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.04 PIK3CA
45 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.04 BRAF
46 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.04 KRAS
47 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.04 CTNNB1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.04 RB1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.04 KRAS
50 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.04 BRAF

MGI Mouse Phenotypes related to Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
2 behavior/neurological MP:0005386 10.51 AKT1 BRAF CDKN2A CTNNB1 EPCAM ERBB2
3 cardiovascular system MP:0005385 10.5 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
4 endocrine/exocrine gland MP:0005379 10.5 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
5 homeostasis/metabolism MP:0005376 10.5 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
6 embryo MP:0005380 10.48 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
7 growth/size/body region MP:0005378 10.47 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
8 digestive/alimentary MP:0005381 10.46 BRAF CDKN2A CTNNB1 EGFR EPCAM ERBB2
9 mortality/aging MP:0010768 10.44 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
10 immune system MP:0005387 10.43 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
11 hematopoietic system MP:0005397 10.42 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
12 integument MP:0010771 10.42 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
13 craniofacial MP:0005382 10.4 BRAF CTNNB1 EGFR ERBB2 ERBB4 FGFR3
14 nervous system MP:0003631 10.39 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
15 neoplasm MP:0002006 10.35 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
16 muscle MP:0005369 10.34 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
17 liver/biliary system MP:0005370 10.26 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
18 normal MP:0002873 10.25 AKT1 BRAF CTHRC1 CTNNB1 EGFR ERBB2
19 hearing/vestibular/ear MP:0005377 10.19 BRAF CTHRC1 CTNNB1 EGFR FGFR3 KRAS
20 limbs/digits/tail MP:0005371 10.19 BRAF CTNNB1 EGFR ERBB2 FGFR3 KRAS
21 adipose tissue MP:0005375 10.18 AKT1 BRAF EGFR PIK3CA RB1 TGFBR2
22 no phenotypic analysis MP:0003012 10.13 CDKN2A CTNNB1 EGFR EPCAM FGFR3 HRAS
23 reproductive system MP:0005389 10.1 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
24 respiratory system MP:0005388 10 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
25 renal/urinary system MP:0005367 9.97 BRAF CTNNB1 EGFR FGFR3 HRAS KRAS
26 pigmentation MP:0001186 9.91 BRAF CDKN2A CTNNB1 EGFR KRAS RB1
27 skeleton MP:0005390 9.83 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
28 vision/eye MP:0005391 9.36 BRAF CDKN2A CTNNB1 EGFR FGFR3 KRAS

Drugs & Therapeutics for Adenocarcinoma

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
3
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
4
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
5
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
6
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
7
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
8
Iressa 18 49 GEFITINIB AstraZeneca May 2003
9
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1087)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
4
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
6
Iron Approved Phase 4,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
7
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
8
Clarithromycin Approved Phase 4 81103-11-9 84029
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
11
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
12
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
13
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
14
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
15
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
16
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
17
Cefazolin Approved Phase 4 25953-19-9 656510 33255
18
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 98-92-0 936
19
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
20
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
21
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
22
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
23
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
24
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
25
acetic acid Approved Phase 4,Phase 2,Not Applicable 64-19-7 176
26
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
27
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
28
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
29
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
30
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
31
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
32
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
33
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
34
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
35
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
36
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
37
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
38
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
40
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
41
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
42
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
43
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 56420-45-2 41867
44
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 2 142340-99-6 60871
45
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
46
Nicotine Approved Phase 4,Phase 3,Not Applicable 54-11-5 942 89594
47
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
48
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
49
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68538-85-2
50
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 7738)
# Name Status NCT ID Phase Drugs
1 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
2 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
3 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
4 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
5 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
6 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
7 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
8 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
9 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
10 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
11 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
12 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
13 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
14 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
15 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
16 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
17 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
18 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
19 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
20 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
21 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
22 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
23 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
24 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
25 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
26 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
27 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
28 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
29 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
30 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
31 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
32 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
33 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
34 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
35 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
36 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
37 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
38 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
39 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
40 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
41 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
42 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
43 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
44 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
45 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
46 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
47 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
48 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
49 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
50 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

# Genetic test Affiliating Genes
1 Adenocarcinoma 29

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

41
Lung, Prostate, Colon, Breast, Pancreas, Cervix, Lymph Node

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 22346)
# Title Authors Year
1
IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis. ( 30540680 )
2019
2
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. ( 30546950 )
2019
3
Occult mucin-producing urothelial-type adenocarcinoma of the prostate with elevated serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9: Report of an autopsy-proven case. ( 30505685 )
2019
4
AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma. ( 30531392 )
2019
5
Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report. ( 30533375 )
2019
6
Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. ( 30452897 )
2019
7
TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool. ( 30467244 )
2019
8
Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. ( 30476732 )
2019
9
Generation of Induced Pluripotent Stem Cell-Like Lines from Human Pancreatic Ductal Adenocarcinoma. ( 30378042 )
2019
10
3D Models of Pancreatic Ductal Adenocarcinoma via Tissue Engineering. ( 30378046 )
2019
11
Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. ( 30378047 )
2019
12
Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma. ( 30378048 )
2019
13
Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis. ( 30387807 )
2019
14
Overexpression of miR‑361‑5p plays an oncogenic role in human lung adenocarcinoma through the regulation of SMAD2. ( 30365047 )
2019
15
Novel 2,3‑disubstituted 1,3‑thiazolidin‑4‑one derivatives as potential antitumor agents in renal cell adenocarcinoma. ( 30365115 )
2019
16
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma. ( 30255938 )
2019
17
Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT. ( 30203487 )
2019
18
Gastric-type Adenocarcinoma of the Cervix: Tumor With Wide Range of Histologic Appearances. ( 30234500 )
2019
19
Methylation of CLEC14A is associated with its expression and lung adenocarcinoma progression. ( 30191970 )
2019
20
Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. ( 30125988 )
2019
21
Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. ( 30138218 )
2019
22
CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. ( 30076728 )
2019
23
Prognostic significance of G6PD expression and localization in lung adenocarcinoma. ( 29753088 )
2019
24
Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients. ( 30230541 )
2019
25
Whole-tumor histogram analysis of non-Gaussian distribution DWI parameters to differentiation of pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas. ( 30240758 )
2019
26
Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )
2018
27
SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )
2018
28
Large Cell Carcinoma with Adenocarcinoma in Lung. ( 29544586 )
2018
29
Cytological features of hepatoid adenocarcinoma of the gallbladder: A case report with immunocytochemical analyzes. ( 29637715 )
2018
30
Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )
2018
31
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
32
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
33
Gastric-type Endocervical Adenocarcinoma Involving the Endometrium and Clinically Mimicking Endometrial Neoplasia: A Diagnostic Challenge. ( 29683820 )
2018
34
Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution. ( 29683879 )
2018
35
Histopathologic Features of Colorectal Adenoma and Adenocarcinoma Developing Within Inflammatory Polyps in Miniature Dachshunds. ( 29852840 )
2018
36
MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. ( 29765447 )
2018
37
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
38
Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma. ( 28796375 )
2018
39
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
40
A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. ( 29700411 )
2018
41
Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): A prospective, randomized, double-blind study. ( 29848836 )
2018
42
Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )
2018
43
Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study. ( 29972732 )
2018
44
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
45
Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma. ( 29976631 )
2018
46
Adenocarcinoma of Pigmented Ciliary Epithelium in a Child With Aicardi Syndrome and Congenital Microphthalmia With Cyst. ( 29342031 )
2018
47
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )
2018
48
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. ( 29608452 )
2018
49
Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. ( 29973215 )
2018
50
In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )
2018